Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CEL-SCI Multikine

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Seven of 10 patients with advanced head and neck cancer who received six 1600 IU injections of the leukocyte interleukin had tumor reductions before surgery or radiation during an 18-day drug treatment period, the company reported. Ten patients each were assigned to one of three dosage groups: 800 IU, 1600 IU, and 3200 IU, given in six injections over 18 days. Six of 10 patients treated with the lowest dose and three of 10 treated with the highest dose experienced tumor reductions. Two patients in the 800 IU group and three patients in the 1600 IU group had a greater than 50% reduction in tumor size. The company reported no significant toxicity. Phase III studies are expected to begin in 2001
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS001050

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel